Clinical Trial

Atacicept in Subjects With IgA Nephropathy

Study acronym: ORIGIN 3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2021-01-15; most recent amendment 2025-09-24.
Status change: Recruiting → Active, Not Recruiting 2025-04-08
Status change: Active, Not Recruiting → Recruiting 2023-05-23
Status change: Recruiting → Active, Not Recruiting 2022-07-06
Status change: Not Yet Recruiting → Recruiting 2021-05-21
Trial Details
NCT Number NCT04716231
Lead Sponsor Vera Therapeutics, Inc.
Conditions IgA Nephropathy, Berger Disease
Enrollment 376 participants
Start Date 2023-06-29
Primary Completion 2025-05-15 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-30